Liyan Mazahreh

Researcher

UAMS

Also affiliated: Hashemite University (2023); Central Arkansas Veterans Healthcare System (2023); Arkansas Department of Agriculture (2022)

Faculty Researcher

2 h-index 14 pubs 149 cited

Research Areas

Biomedical Subjects

OverviewAI-generated summary

Liyan Mazahreh's research investigates the clinical aspects of various medical conditions, with a particular focus on oncology and infectious diseases. Mazahreh has published on the risk of infections associated with bispecific antibodies in patients with multiple myeloma, analyzing pooled data to understand treatment-related complications. Further work explores tumor response to immune-oncology therapies in the context of steroid intervention and autoimmune conditions, as well as the duration of immune checkpoint inhibitors in oncology. Mazahreh has also examined hospitalizations and the severity of asthma exacerbations in children during non-pharmaceutical interventions and investigated eosinophilic chronic rhinosinusitis. Collaborations include extensive work with Farah Mazahreh and A. Mazin Safar at the University of Arkansas for Medical Sciences. Mazahreh's scholarly output includes 14 publications with an h-index of 2 and 146 citations.

Metrics

h-index: 2
Publications: 14
Citations: 149

Selected Publications

Abstract 3051: Enhancing matchmaking in targeted therapy (TT) for cancer (ca): Beyond the ‘arranged’ criteria (2026)

Cancer Research DOI OpenAlex
Abstract 6288: Rational pairing of tumors with off-patent targeted therapies (TT): Next3 generation sequencing with global applications for the unprivileged patients. (2026)

Cancer Research DOI OpenAlex
Hospitalizations and Severity of Rhinovirus-Associated Asthma Exacerbations in Children During the Institution of Non-pharmaceutical Interventions (2026)

Journal of Allergy and Clinical Immunology DOI OpenAlex
Exploring new frontiers in eosinophilic chronic rhinosinusitis (2025)

Annals of Allergy Asthma & Immunology DOI OpenAlex
Abstract 3214: The duration of immune checkpoint inhibitors (ICI) in oncology: Longer is not better (2025)

Cancer Research DOI OpenAlex
Ongoing Radiographic Response for Over 20 Months in Metastatic Cancer Without Continued Immune Checkpoint Inhibitor (ICI) Dosing (2025)

Cureus DOI OpenAlex
Tumor Response to Immune-Oncology Therapy Despite High-Dose Steroid Intervention in a Patient With Papillary Renal Cell Carcinoma and Immune-Related Myasthenia Gravis (2025)

Cureus 2 citations DOI OpenAlex
Abstract 1177: The chronology of immune-related adverse events (irAEs)-mechanistic implications (2024)

Cancer Research DOI OpenAlex